TOP TEN perturbations for 39426_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39426_at
Selected probe(set): 229706_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39426_at (229706_at) across 6674 perturbations tested by GENEVESTIGATOR:

conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-3.185052
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS5)
CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

conditioned medium study 1 (HS27a) / untreated monocyte (CD14+) sample

Relative Expression (log2-ratio):-3.1016273
Number of Samples:2 / 2
Experimental conditioned medium study 1 (HS27a)
CD14+ monocytes treated with HS27a conditioned medium (CM) for 48h.
Control untreated monocyte (CD14+) sample
Untreated CD14+ monocytes from two different donors.

DLBCL study 1 (activated B-cell like; naïve-like) / DLBCL study 1 (activated B-cell like; centrocyte-like)

Relative Expression (log2-ratio):-2.3555584
Number of Samples:2 / 8
Experimental DLBCL study 1 (activated B-cell like; naïve-like)
Naive B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).
Control DLBCL study 1 (activated B-cell like; centrocyte-like)
Centrocyte B-cells sorted from primary tumor samples from patients with malignant diffuse large B-cell lymphoma (activated B-cell like type). To isolate different B-cell subsets, tonsil tissues from DLBCL patients were sorted by fluorescence-activated cell sorting. Samples were also classified based on subset-specific B-cell-associated gene signature (BAGS).

glioma study 16 (BS-149) / normal astrocyte sample

Relative Expression (log2-ratio):-2.3285117
Number of Samples:2 / 3
Experimental glioma study 16 (BS-149)
Human glioma cell line BS149 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant)

Relative Expression (log2-ratio):2.1906967
Number of Samples:9 / 30
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant)
Whole blood obtained from infants (1 month – 1 year) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Five children did not survive.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):-2.1476984
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

pediatric septic shock study 3 (toddler; subclass C) / pediatric septic shock study 3 (toddler)

Relative Expression (log2-ratio):2.1304417
Number of Samples:14 / 23
Experimental pediatric septic shock study 3 (toddler; subclass C)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (toddler)
Whole blood obtained from toddlers (2 – 5 years) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit (day 1). Two children did not survive.

Crohn's disease study 10 / colorectal cancer study 14 (tvvad)

Relative Expression (log2-ratio):-2.1127472
Number of Samples:4 / 2
Experimental Crohn's disease study 10
Colon biopsies derived from patients with Crohn's disease.
Control colorectal cancer study 14 (tvvad)
Colon biopsies derived from patients with high grade tubulovillous/villous adenoma.

lactic acidosis study 1 (24h) / control media treated MCF-7 cell sample

Relative Expression (log2-ratio):-2.0826159
Number of Samples:3 / 3
Experimental lactic acidosis study 1 (24h)
MCF-7 breast cancer cells exposed to lactic acidosis for 24 hours. Cells were serum starved for 24 hours before exposure to lactic acidosis conditions, that were created with the addition of 25mM lactic acid.
Control control media treated MCF-7 cell sample
MCF-7 breast cancer cells treated with control media for 24 hours. Cells were serum starved for 24 hours before treatment with control media (DMEM with 4.5 g/L glucose, supplemented with 10% fetal bovine serum, 1× non-essential amino acid and 1× antibiotics (penicillin, 10000UI/ml; streptomycin, 10000UI/ml).

glioma study 16 (LN-319) / normal astrocyte sample

Relative Expression (log2-ratio):-2.0126143
Number of Samples:2 / 3
Experimental glioma study 16 (LN-319)
Human glioma cell line LN319 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

Organism: Homo sapiens
Gene: 39426_at
Selected probe(set): 202396_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39426_at (202396_at) across 6674 perturbations tested by GENEVESTIGATOR:

pediatric septic shock study 3 (infant; subclass A) / normal blood sample (infant)

Relative Expression (log2-ratio):-2.92377
Number of Samples:8 / 17
Experimental pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (infant)
Whole blood samples from infants (1 month – 1 year). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

FoxO3 H212R overexpr. study 1 / FoxO3 overexpr. study 1

Relative Expression (log2-ratio):-2.579112
Number of Samples:3 / 3
Experimental FoxO3 H212R overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP FoxO3.A3.ER.H212R vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of mutated FoxO3 (forkhead box O3) H212R, treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---
Control FoxO3 overexpr. study 1
Human umbilical vein endothelial cells (HUVECs) transfected with retroviral pBP-FoxO3.A3.ER vector for 4OHT (4-hydroxy-(Z)-tamoxifen) inducible expression of FoxO3 (forkhead box O3), treated with 4OHT for 12 hours. 72 hours postinfection, cells were selected for puromycin resistance by adding 2 g/ml puromycin overnight. Further, cells were reseeded in puromycin-free medium, treated for 12 hours with 4OHT, and harvested for total RNA isolation. Cells from passage 3 were used for infection and maximally passaged once for the experiments. ATC code:---

LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.5691395
Number of Samples:2 / 2
Experimental LPS study 4 (shRNA contr.)
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated / transduced MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):-2.4516878
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

brefeldin A study 1 (0.5ug/ml; p53HCT116) / untreated p53HCT116 cell sample

Relative Expression (log2-ratio):2.350463
Number of Samples:2 / 3
Experimental brefeldin A study 1 (0.5ug/ml; p53HCT116)
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated p53HCT116 cell sample
Derived human colon carcinoma cell line p53HCT116 with knockout gene for p53 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

endometriosis study 6 (minimal/mild endo.; pro. MCP) / normal endometrium tissue (pro. MCP)

Relative Expression (log2-ratio):-2.3347788
Number of Samples:12 / 20
Experimental endometriosis study 6 (minimal/mild endo.; pro. MCP)
Endometrial tissue samples from women with minimal or mild endometriosis and pelvic pain and/or infertility collected in the proliferative menstrual cycle phase (MCP). Endometriosis was diagnosed based on the revised American Fertility Society classification system. The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis. Patients with hormonal treatment within previous 3 months and presence of malignancy or major systemic disease were excluded.
Control normal endometrium tissue (pro. MCP)
Normal endometrial tissue samples from women collected in the proliferative menstrual cycle phase (MCP). The MCP was determined by endometrial histology, confirmed by estradiol and progesterone serum levels and corroborated by 2 independent bioinformatics methods: clustering in unsupervised whole-transcriptome principal component analysis and cycle phase assignment classifier analysis.

pediatric septic shock study 3 (toddler; subclass A) / normal blood sample (toddler)

Relative Expression (log2-ratio):-2.3278017
Number of Samples:4 / 18
Experimental pediatric septic shock study 3 (toddler; subclass A)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. One child did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (toddler)
Whole blood samples from toddlers (2 – 5 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

nephroblastoma study 2 / normal kidney tissue (adult)

Relative Expression (log2-ratio):2.2600079
Number of Samples:4 / 3
Experimental nephroblastoma study 2
Tumor tissue samples from the kidney of patients with Wilms’ tumor.
Control normal kidney tissue (adult)
Normal adult kidney tissue samples.

pediatric septic shock study 3 (infant; subclass C) / pediatric septic shock study 3 (infant; subclass A)

Relative Expression (log2-ratio):2.2544756
Number of Samples:9 / 8
Experimental pediatric septic shock study 3 (infant; subclass C)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass C. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. All children survived. The subclass C was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients from subclass C (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.7 - 19.2), maximum number of organ failures 2 (IQR 2 - 2), and a low mortality rate.
Control pediatric septic shock study 3 (infant; subclass A)
Whole blood samples obtained from infants (1 month – 1 year) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.

pediatric septic shock study 3 (school-age; subclass A) / normal blood sample (school-age)

Relative Expression (log2-ratio):-2.2227316
Number of Samples:6 / 9
Experimental pediatric septic shock study 3 (school-age; subclass A)
Whole blood samples obtained from school-age children (≥ 6 years) with septic shock subclass A. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Three children did not survive. The subclass A was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass A (when all age groups were pooled) had a significantly higher illness severity level (PRISM III score = 20.5, intra-quartile range (IQR) 12.5 – 32.5), a greater degree of organ failure – maximum number of organ failures 3 (IQR 3 - 4), and a higher mortality rate, a significantly higher incidence of documented Gram-positive bacterial infection and were significantly younger compared with other subclasses.
Control normal blood sample (school-age)
Whole blood samples from school-age children (≥ 6 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.